Patient-Focused Drug Development Public Meeting and Scientific workshop on Female Sexual Dysfunction

FDA is conducting a Patient-Focused Drug Development public meeting and scientific workshop on Female Sexual Dysfunction (FSD) on October 27 and October 28.

Day 1 – October 27th Patient-Focused Drug Development Public Meeting
FDA is interested in obtaining patient input on:
1. The impact of the most common form of FSD, female sexual interest/arousal disorder (FSIAD) on daily life
2. Patients’ views on currently available therapies to treat the condition

Day 2 – October 28th Scientific Workshop
The scientific workshop will include discussion on scientific challenges related to:
1. Diagnosis of the condition for clinical trials and in clinical practice
2. Ensuring valid patient-reported outcome measures for the key efficacy endpoints used in clinical trials

Date(s) and Time(s)
October 27, 2014 (12:00 p.m. to 5:00 p.m.)
October 28, 2014 (8:00 a.m. to 5:00 p.m.)

Location
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 B and C
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)

Remote access will be available via live webcast for those unable to attend in person.

Registration
To register for this meeting, visit http://patient-focused-female-sexual-dysfunction.eventbrite.com. Please note that registration for in-person attendance and the webcast closes on October 20, 2014.